Abstract: The invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1 as shown in the Figure, and fragments and variants thereof capable of antagonizing the heterodimerization of a DP protein with an E2F protein. Such peptides may be used to induce apoptosis in a cell by introducing into the cell an effective amount of said peptide. Such cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis.

Abstract: The present invention provides assays for determining transcription-modulating substances. The transcription-modulating activity of test compounds is assessed on the basis of their ability to suppress or enhance complex formation between Myc and a novel zinc finger binding protein, Miz-1, or derivatives thereof.

Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(?O)2NR1— and —NR1S(?O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(?O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

Abstract: Two novel transcription factors belonging to the E2F gene family, are disclosed. These are human and murine E2F-5. They can interact with DP-1 and p130.

Abstract: The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumors, for assays for compounds useful in the prevention of tumors and compounds obtainable by such assays.

Abstract: Two novel transcription factors belonging to the E2F gene family, are disclosed. These are human and murine E2F-5. They can interact with DP-1 and p130.

Abstract: The invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1 as shown in the Figure, and fragments and variants thereof capable of antagonizing the heterodimerization of a DP protein with an E2F protein. Such peptides may be used to induce apoptosis in a cell by introducing into the cell an effective amount of said peptide. Such cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis.

Abstract: The present invention provides nuclear localisation signals derived from the DP-3 and E2F-1 transcription factors and the use of these signals in assays for regulators of cell cycle progression. Such assays involve using the signals to direct a marker gene to the nucleus and determining whether the nuclear localisation of the marker is disrupted by the presence of a putative regulator.

Abstract: The transcription factor E2F contains a ubiquitination domain. Assays for inhibitors and enhancers of the domain are provided. An assay method for an inhibitor of transcription factor E2F ubiquitin-mediated degradation comprises a) bringing a polypeptide which contains a domain which renders E2F a substrate for ubiquitination into contact with a candidate inhibitor; and b) determining whether or not the candidate inibitor is capable of reducing ubiquitination of the polypeptide. An assay method for an enhancer of transcription factor E2F ubiquitin-mediated degradation may comprise a) bringing a polypeptide which contains a domain which renders E2F a substrate for ubiquitination into contact with a candidate enhancer; and b) determining whether or not the candidate enhancer is capable of enhancing ubiquitination of said polypeptide.

Abstract: The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

Abstract: A novel transcription factor, belong to the E2f gene family, is disclosed. This is called E2F-4. It interacts with DP-1 and can be regulated by p107.

Abstract: The invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1 as shown in the Figure, and fragments and variants thereof capable of antagonising the heterodimerization of a DP protein with an E2F protein. Such peptides may be used to induce apoptosis in a cell by introducing into the cell an effective amount of said peptide. Such cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis.

Abstract: The present invention provides nuclear localisation signals derived from the DP-3 and E2F-1 transcription factors and the use of these signals in assays for regulators of cell cycle progression. Such assays involve using the signals to direct a marker gene to the nucleus and determining whether the nuclear localisation of the marker is disrupted by the presence of a putative regulator.

Abstract: Novel Myc-binding zinc finger proteins, their preparation and their use are provided.

Abstract: A novel transcription factor, belong to the E2f gene family, is disclosed. This is called E2F-4. It interacts with DP-1 and can be regulated by p107.

Abstract: The present invention relates to the finding that cyclin D1 interacts with estrogen receptor to provide activation of estrogen responsive genes. The present invention provides in vitro and in vivo assays to measure the interaction. The in vivo assays may be conducted in cells which grow in response to estrogen, particularly breast tumour cells.

Abstract: The present invention relates to a transcription inhibiting factor, designated BS69. The factor can bind to both the 243R and 289R E1A adenovirus proteins, inhibiting the transactivating activity of the latter.

Abstract: The invention provides polypeptides of transcription factor DP-3 which exists in four isoforms produced by alternative splicing of mRNA, nucleic acid encoding the polypeptides and the use of such nucleic acid and polypeptides in assays. Two isoforms of DP-3 contain a region, designated the E region, which is a nuclear localization signal and is involved in a further level of regulation of DP-3 and its ability to bind to E2F-1 and regulate the cell cycle.